Showing 37 to 48 of 217 results
FDA Recommends Ban on Kratom Byproduct 7-OH Amidst Overdose Concerns
The FDA recommends banning 7-hydroxymitragynine (7-OH), a concentrated kratom byproduct with morphine-like effects, due to a rise in overdoses and unregulated sales at gas stations and vape shops, posing significant public health risks.
FDA Recommends Ban on Kratom Byproduct 7-OH Amidst Overdose Concerns
The FDA recommends banning 7-hydroxymitragynine (7-OH), a concentrated kratom byproduct with morphine-like effects, due to a rise in overdoses and unregulated sales at gas stations and vape shops, posing significant public health risks.
Progress
56% Bias Score
Cancer Drugs Show Promise in Reversing Alzheimer's in Mice
Research shows that the FDA-approved cancer drugs letrozole and irinotecan, when combined, reduced brain degeneration and improved memory in mice, offering a potential new Alzheimer's treatment that could significantly reduce development time and cost.
Cancer Drugs Show Promise in Reversing Alzheimer's in Mice
Research shows that the FDA-approved cancer drugs letrozole and irinotecan, when combined, reduced brain degeneration and improved memory in mice, offering a potential new Alzheimer's treatment that could significantly reduce development time and cost.
Progress
48% Bias Score
FDA Panel Urges Removal of Black Box Warnings for Low-Dose Vaginal Estrogen
An FDA panel recently recommended removing black box warnings from low-dose vaginal estrogen treatments due to concerns that they overstate risks and deter women from using beneficial menopause medications; this decision follows decades of evolving understanding of HRT safety and efficacy.
FDA Panel Urges Removal of Black Box Warnings for Low-Dose Vaginal Estrogen
An FDA panel recently recommended removing black box warnings from low-dose vaginal estrogen treatments due to concerns that they overstate risks and deter women from using beneficial menopause medications; this decision follows decades of evolving understanding of HRT safety and efficacy.
Progress
48% Bias Score
FDA to Ban Prescription Fluoride Supplements Amidst Rising Demand
The FDA plans to ban prescription fluoride supplements by late October, despite rising demand due to state-level bans on community water fluoridation, sparking concerns about oral health equity.
FDA to Ban Prescription Fluoride Supplements Amidst Rising Demand
The FDA plans to ban prescription fluoride supplements by late October, despite rising demand due to state-level bans on community water fluoridation, sparking concerns about oral health equity.
Progress
32% Bias Score
FDA Panel on Antidepressants During Pregnancy Draws Criticism for Misinformation
An FDA panel's discussion on using antidepressants during pregnancy sparked controversy, with psychiatrists criticizing the presentation of misinformation and unbalanced viewpoints that contradict established medical consensus on SSRIs and the risks of untreated depression.
FDA Panel on Antidepressants During Pregnancy Draws Criticism for Misinformation
An FDA panel's discussion on using antidepressants during pregnancy sparked controversy, with psychiatrists criticizing the presentation of misinformation and unbalanced viewpoints that contradict established medical consensus on SSRIs and the risks of untreated depression.
Progress
60% Bias Score
FDA Authorizes Juul E-Cigarette Sales
The FDA authorized Juul Labs to continue selling its e-cigarettes in the U.S. after a multiyear review, citing evidence of adult smokers switching from traditional cigarettes, despite concerns about youth vaping and potential health risks.
FDA Authorizes Juul E-Cigarette Sales
The FDA authorized Juul Labs to continue selling its e-cigarettes in the U.S. after a multiyear review, citing evidence of adult smokers switching from traditional cigarettes, despite concerns about youth vaping and potential health risks.
Progress
44% Bias Score
Sarepta Stock Surges After FDA Lifts Hold on Elevidys
Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.
Sarepta Stock Surges After FDA Lifts Hold on Elevidys
Following the FDA's decision to lift the clinical hold on its Elevidys drug, Sarepta Therapeutics' stock price rose to approximately $19 in extended trading, driven by increased revenue potential and a company restructuring plan aiming for $400 million in annual cost savings by 2026.
Progress
44% Bias Score
FDA Panel Recommends Removing Black Box Warning from Some Menopause Treatments
The FDA may remove the black box warning on estrogen-containing menopause treatments following an expert panel's recommendation, based on updated analyses suggesting that hormone therapy may not increase risks as previously thought, particularly when initiated before age 60 or within 10 years of men...
FDA Panel Recommends Removing Black Box Warning from Some Menopause Treatments
The FDA may remove the black box warning on estrogen-containing menopause treatments following an expert panel's recommendation, based on updated analyses suggesting that hormone therapy may not increase risks as previously thought, particularly when initiated before age 60 or within 10 years of men...
Progress
36% Bias Score
High Triglycerides Increase Cardiovascular Risk: Treatment and Prevention
High triglycerides, a common type of fat, increase cardiovascular risk when elevated, often alongside high LDL cholesterol; treatments include statins, lifestyle changes, and medications like niacin, fibrates, or omega-3 fatty acids, with icosapent ethyl showing promise in reducing cardiovascular ev...
High Triglycerides Increase Cardiovascular Risk: Treatment and Prevention
High triglycerides, a common type of fat, increase cardiovascular risk when elevated, often alongside high LDL cholesterol; treatments include statins, lifestyle changes, and medications like niacin, fibrates, or omega-3 fatty acids, with icosapent ethyl showing promise in reducing cardiovascular ev...
Progress
32% Bias Score
FDA Weighs Ban on Fluoride Supplements Amidst Conflicting Scientific Evidence
An FDA meeting on fluoride supplements revealed conflicting views on their impact on children's microbiomes and their role in preventing tooth decay; a final decision is pending, highlighting concerns about access to oral healthcare in underserved communities.
FDA Weighs Ban on Fluoride Supplements Amidst Conflicting Scientific Evidence
An FDA meeting on fluoride supplements revealed conflicting views on their impact on children's microbiomes and their role in preventing tooth decay; a final decision is pending, highlighting concerns about access to oral healthcare in underserved communities.
Progress
36% Bias Score
FDA Authorizes Juul E-Cigarettes Amidst Ongoing Controversy
The FDA authorized Juul's e-cigarettes for sale to adult smokers, reversing an earlier decision, based on studies suggesting reduced harm compared to traditional cigarettes; this decision sparks controversy due to Juul's history of contributing to youth vaping.
FDA Authorizes Juul E-Cigarettes Amidst Ongoing Controversy
The FDA authorized Juul's e-cigarettes for sale to adult smokers, reversing an earlier decision, based on studies suggesting reduced harm compared to traditional cigarettes; this decision sparks controversy due to Juul's history of contributing to youth vaping.
Progress
48% Bias Score
Biden Administration to Fast-Track Psychedelic Therapy Approvals
The Biden administration plans to fast-track approval of psychedelic therapies within 12 months, spurred by Health Secretary Robert F. Kennedy Jr., while Texas commits $50 million to ibogaine research, despite concerns about insufficient scientific evidence and potential risks.
Biden Administration to Fast-Track Psychedelic Therapy Approvals
The Biden administration plans to fast-track approval of psychedelic therapies within 12 months, spurred by Health Secretary Robert F. Kennedy Jr., while Texas commits $50 million to ibogaine research, despite concerns about insufficient scientific evidence and potential risks.
Progress
48% Bias Score
Showing 37 to 48 of 217 results